Small Molecules for Precision Medicine

Learn More about Arqule

We are pursuing multiple programs in biomarker-defined oncology and rare disease indications

Targeted Approach to Cancer

Clinical Trials

Learn More

Research & Development

Product Pipeline

Explore

Targeted Approach To

Rare Diseases

Read More

News & Events

April 7, 2016
Proteus Syndrome Treatment
Watch Video »
June 23, 2017
ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA)
Read More »
June 7, 2017
ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases
Read More »

More News & Events »

arqule

© Copyright ArQule. All rights reserved. Terms of Use.